ArticleMedical care2009
Changes over time and disparities in schizophrenia treatment quality.
Article in Medical care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Identifying primary care quality indicators for people with serious mental illness: a systematic review.The British journal of general practice : the journal of the Royal College of General Practitioners · 2017Pooled it
- Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis.Social psychiatry and psychiatric epidemiology · 2013Pooled it
- The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.Schizophrenia bulletin · 2010Guideline
- Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study.The American journal of psychiatry · 2015Trial
- Hospital Length of Stay in Patients with and without Serious and Persistent Mental Illness: Evidence of Racial and Ethnic Differences.Healthcare (Basel, Switzerland) · 2022Article
- Disruptions in Care for Medicare Beneficiaries With Severe Mental Illness During the COVID-19 Pandemic.JAMA network open · 2022Article
- Antipsychotic medication adherence and preventive diabetes screening in Medicaid enrollees with serious mental illness: an analysis of real-world administrative data.BMC health services research · 2021Article
- Implementing parity for mental health and substance use treatment in Medicaid.Health services research · 2020Article
- Impact of family practice continuity of care on unplanned hospital use for people with serious mental illness.Health services research · 2019Observational
- Racial/ethnic disparities in specialty behavioral health care treatment patterns and expenditures among commercially insured patients in managed behavioral health care plans.Health services research · 2019Article
- The Effects of the Transition From Medicaid to Medicare on Health Care Use for Adults With Mental Illness.Medical care · 2016Article
- Racial-Ethnic Differences in Psychiatric Diagnoses and Treatment Across 11 Health Care Systems in the Mental Health Research Network.Psychiatric services (Washington, D.C.) · 2016Article
- Thirty-Day Hospital Readmission for Medicaid Enrollees with Schizophrenia: The Role of Local Health Care Systems.The journal of mental health policy and economics · 2015Observational
- State Variation in the Delivery of Comprehensive Services for Medicaid Beneficiaries with Schizophrenia and Bipolar Disorder.Community mental health journal · 2015Article
- Individual and contextual-level factors associated with continuity of care for adults with schizophrenia.Administration and policy in mental health · 2014Article
- The development of the DSM-5 Cultural Formulation Interview-Fidelity Instrument (CFI-FI): a pilot study.Journal of health care for the poor and underserved · 2014Article
- Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002-2008.Health services research · 2014Article
- Guideline-concordant antipsychotic use and mortality in schizophrenia.Schizophrenia bulletin · 2013Article
- Measuring disparities across the distribution of mental health care expenditures.The journal of mental health policy and economics · 2013Article
- Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory.Pharmacoepidemiology and drug safety · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSchizophrenia medication and psychosocial treatment options have expanded since the Schizophrenia PORT was conducted. However, there also have been considerable changes in the delivery of mental health care in the public sector, as well as increasing state concerns about Medicaid cost containment.
objectivesTo examine trends and patient characteristics associated with differences in schizophrenia medication and visit treatment quality in a Medicaid population. RESEARCH
designObservational study of claims data from July 1, 1996 to June 30, 2001. SUBJECTS: Florida Medicaid enrollees diagnosed with schizophrenia (N = 23,619). MEASURES: We examined the likelihood of meeting any 1 and all 4 of the following quality standards: (1) receiving antipsychotic medication, (2) antipsychotic continuity, (3) dosing consistent with PORT recommendations, and (4) mental health visit continuity. Separate models were fit for acute and maintenance phases of treatment.
resultsApproximately 18% of acute and 7% of maintenance phases met all 4 quality standards. Antipsychotic quality improved (largely driven by an increasingly likelihood of receiving any antipsychotic), while visit continuity declined. The greatest disparities were seen for persons with co-occurring substance use disorders and of black race. Quality differences were often phase specific and at times in opposite directions across treatment phases.
conclusionsThe improvement in antipsychotic treatment quality is encouraging. However, visit continuity declined. This study highlights the importance of quality measurement that includes focus on different treatment modalities and phases of care, as well as for potentially vulnerable populations (such as persons with co-occurring substance use disorders and racial/ethnic minorities).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.